eMedicine Specialties > Pediatrics: Surgery > General Surgery
Crohn Disease: Surgical Perspective
Updated: Jul 6, 2006
Introduction
Crohn disease is a chronic disease that primarily affects young individuals. Although its etiology is unknown, recent findings regarding the genetic and immunologic features of Crohn disease have provided insight into the possible mechanisms of pathogenesis. Corticosteroids have been the mainstay of medical treatment in patients with active inflammation, but salicylates, antibiotics, and immunosuppressants have also shown benefit. Biologic therapies involving antibodies, antisense oligonucleotides, and cytokines are promising new medical therapies. Surgical treatment has been reserved for refractory disease and complications. Minimally invasive surgery has provided an alternative to the traditional open surgical approach.
History of the Procedure
In 1932, the article "Regional Ileitis" by Crohn, Ginzburn, and Oppenheimer appeared in the Journal of the American Medical Association. This landmark article described findings in a series of 14 patients with a disease of the terminal ileum characterized by subacute or chronic necrotizing and cicatrizing inflammation. Since then, Crohn disease has been found to occur in all parts of the gastrointestinal tract and to have widespread extraintestinal manifestations. The pathologic criteria to distinguish Crohn disease from other forms of inflammatory bowel disease were not established until 1960.
Problem
Crohn disease predominantly affects a young population and is a chronic incurable condition. It requires ongoing medical management and causes long-term pain and disability. Frequent surgical interventions are often required to treat complications. The understanding of this disease in incomplete, but advances in medical therapies and surgical techniques have led to an improvement in patients' quality of life.
Frequency
The incidence of Crohn disease in the general population is approximately 5.3 cases per 100,000 persons. The onset of the disease peaks in older adolescents and young adults. However, approximately 5% of new cases occur in children younger than 5 years. Crohn disease affects persons of every ethnic origin, but it is most common in the Ashkenazi Jewish and Caucasian populations. Male and female individuals are affected with equal frequency.
Etiology
The etiology of Crohn disease is unknown. Its pathogenesis is likely multifactorial, involving a combination of infectious agents and environmental exposures that activate an immune response in a genetically susceptible host. Familial clustering of Crohn disease suggests a genetic etiology. A positive family history is found in 10-15% of patients. The relative risk for first-degree relatives of these patients is estimated to be 10-21 times that of the general population. Disease locations and types (eg, stricturing, inflammatory, perforating) tend to be similar among family members. Other genetic abnormalities linked with Crohn disease include hereditary conditions such as glycogen storage disease type 1b and dysfunction of the complement pathway.
Bacterial agents have long been thought to be involved in the pathogenesis of Crohn disease, though no bacteria have been definitively identified. Therefore, in the multifactorial model, the interaction of bacteria, immune mechanisms, and genetic susceptibility may be necessary for the development of the disease.
Environmental factors, such as smoking and exposure to second-hand smoke, have been linked to Crohn disease. Concerns about the measles vaccine in the development of Crohn disease have been unfounded. Although appendectomy has been suggested to be protective in ulcerative colitis, it is not a protective in Crohn disease.
Pathophysiology
Crohn disease can affect any part of the alimentary tract from the mouth to the anus. The most common site is the terminal ileum. The appendix is often involved as well. The disease is often segmental (unlike ulcerative colitis), and the rectum is frequently spared.
On endoscopy, Crohn disease typically appears as patchy areas of inflammation separated by uninvolved bowel. The earliest lesions are aphthous ulcers, ie, tiny, discrete erosions that typically occur over lymphoid follicles. As the disease progresses, interconnecting rows of aphthous ulcers create linear ulcers. These linear ulcers cross transverse folds, contributing to a cobblestone appearance.
On gross examination, surgical specimens are rigid and thickened as a result of chronic inflammation and fibrosis during healing periods. The mesentery is typically thickened and foreshortened and may partly surround the bowel wall in a phenomenon known as creeping fat (see Image 1). The transmural nature of inflammation contributes to possible fistulous connections between segments of bowel or other organs.
Presentation
The differential diagnosis of Crohn disease includes infections, such as bacterial enteritis, giardiasis, amoebiasis, viral gastroenteritis, and granulomatous disease, or other inflammatory conditions, such as ulcerative colitis.
Crohn disease most commonly presents in an adolescent or young adult with chronic abdominal pain, diarrhea, and weight loss. Patients presenting with Crohn colitis may additionally have bloody diarrhea, tenesmus, or incontinence. A small group of children initially present for treatment because of secondary amenorrhea or a delayed onset of puberty.
Approximately 5% of patients present with only perianal symptoms. Anal fissures are the most common finding in perianal disease. They are often located eccentrically rather than in the classic posterior midline position of most benign fissures. Skin tags, anal stenosis, fecal incontinence, fistula, and perianal abscesses are also common signs and symptoms of perianal disease.
On occasion, a patient's initial presentation is for the treatment of a complication of Crohn disease. Although more common in ulcerative colitis, toxic megacolon can be a life-threatening manifestation of Crohn disease. Small-bowel obstruction, intestinal perforation, intra-abdominal abscess, or enteric fistulas can also be part of the initial presentation. Because symptoms of ileitis may mimic those of appendicitis, the diagnosis may be made at the time of appendectomy.
Of interest, extraintestinal manifestations of Crohn disease may develop first. Many of these extraintestinal signs overlap with those of ulcerative colitis. Aphthous ulcerations of the buccal mucosa, lips, or tongue should alert the clinician to assess for intestinal involvement. Skin manifestations, such as erythema nodosum and pyoderma gangrenosum, occur more commonly in Crohn disease then in ulcerative colitis. These occur predominantly on the lower legs over the tibia.
Ankylosing spondylitis is more common in men with Crohn disease than in women. Ocular symptoms, such as iritis and uveitis, and hepatic involvement with chronic hepatitis or sclerosing cholangitis may be observed, though these are most commonly associated with ulcerative colitis than with Crohn disease. Renal calculi and cholelithiasis are complications of long-standing ileal disease.
Children commonly have growth failure as an extraintestinal manifestation of inflammatory bowel disease. This growth failure results from both decreased caloric intake and circulating inflammatory cytokines. Growth failure is defined by using several parameters, including height below the third percentile, a shift to a lower height percentile, or reduced growth velocity. Enteral feeding is the first-line treatment. However, achieving remission of the inflammation is critical to maintaining growth. If intensive medical treatment does not result in remission, surgical intervention may be warranted, particularly for isolated small-bowel disease.
Indications
Because Crohn disease cannot be cured with surgical intervention, the goal is palliation of active symptoms and disease remission. Indications for surgery include intractable disease, growth retardation, cancer, perianal disease, and complications of intestinal disease, such as stricture, intestinal obstruction, and enteric, colonic, or vesicular fistulas. In children with recurrent acute episodes, the potential for further bowel loss must be weighed against the risks of long-term steroid therapy and failure to thrive.
Indications for surgical intervention in patients with Crohn disease can be summarized as follows:
- Failure of medical therapy
- Complications of steroid or other medical therapy (eg, growth failure)
- Complications of the disease process
- Intestinal obstruction (especially of the terminal ileum)
- Intestinal perforation
- Intestinal bleeding
- Recalcitrant sepsis
Relevant Anatomy
See Pathophysiology.
Contraindications
The operative management of Crohn disease remains one of the most challenging areas of surgery. Surgery is generally reserved for refractory disease or intestinal complications. Resection of asymptomatic disease is not warranted because disease recurrence is the rule.
Although surgical options are expanding, Crohn disease is an important contraindication for creation of a Kock pouch. Patients with Crohn disease who receive a Kock pouch ultimately require resection of the pouch or continuing treatment for severe pouchitis.
More on Crohn Disease: Surgical Perspective |
 Overview: Crohn Disease: Surgical Perspective |
| Workup: Crohn Disease: Surgical Perspective |
| Treatment: Crohn Disease: Surgical Perspective |
| Follow-up: Crohn Disease: Surgical Perspective |
| Multimedia: Crohn Disease: Surgical Perspective |
| References |
| Next Page » |
References
Aleali M, Milsom JW. Laparoscopic surgery in Crohn''s disease. Surg Clin North Am. Feb 2001;81(1):217-30, x. [Medline].
Aufses AH Jr. The history of Crohn''s disease. Surg Clin North Am. Feb 2001;81(1):1-11, vii. [Medline].
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. Apr 2001;96(4):1116-22. [Medline].
Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn''s disease with metronidazole. Gastroenterology. Sep 1980;79(3):599. [Medline].
Bond JH. Colorectal cancer update. Prevention, screening, treatment, and surveillance for high-risk groups. Med Clin North Am. Sep 2000;84(5):1163-82, viii. [Medline].
Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn''s disease. N Engl J Med. Sep 28 1989;321(13):845-50. [Medline].
Chen HH, Wexner SD, Iroatulam AJ, et al. Laparoscopic colectomy compares favorably with colectomy by laparotomy for reduction of postoperative ileus. Dis Colon Rectum. Jan 2000;43(1):61-5. [Medline].
Church JM. Molecular genetics and Crohn''s disease. Surg Clin North Am. Feb 2001;81(1):31-8, vii-viii. [Medline].
Couckuyt H, Gevers AM, Coremans G, et al. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn''s strictures: a prospective long-term analysis. Gut. Apr 1995;36(4):577-80. [Medline].
D''haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn''s disease: A European multicenter trial. Gastroenterology. May 1999;116(5):1029-34. [Medline].
Davis RL, Kramarz P, Bohlke K, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med. Mar 2001;155(3):354-9. [Medline].
Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn''s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion. 1989;42(4):224-32. [Medline].
Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. Oct 1998;93(10):1860-6. [Medline].
Florie J, Horsthuis K, Hommes DW, et al. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin Gastroenterol Hepatol. Dec 2005;3(12):1221-8. [Medline].
Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn''s disease: outcome of medical versus surgical treatment. J Clin Gastroenterol. May-Jun 2001;32(5):409-12. [Medline].
Gavin J, Anderson CE, Bremner AR, Beattie RM. Energy intakes of children with Crohn's disease treated with enteral nutrition as primary therapy. J Hum Nutr Diet. Oct 2005;18(5):337-42. [Medline].
Georgeson KE, Cohen RD, Hebra A, et al. Primary laparoscopic-assisted endorectal colon pull-through for Hirschsprung''s disease: a new gold standard. Ann Surg. May 1999;229(5):678-82; discussion 682-3. [Medline].
IBD Working Group. Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Inflammatory Bowel Disease in Children and Adolescents: Recommendations for Diagnosis-The Porto Criteria. J Pediatr Gastroenterol Nutr. 2005;41:1-7.
Lang KA, Peppercorn MA. Promising new agents for the treatment of inflammatory bowel disorders. Drugs R D. Mar 1999;1(3):237-44. [Medline].
Langer JC. Crohn disease. In: Surgery of Infants and Children. Philadelphia, Pa:. Lippincott-Raven;1997:1253.
Langer JC, Seifert M, Minkes RK. One-stage Soave pull-through for Hirschsprung''s disease: a comparison of the transanal and open approaches. J Pediatr Surg. Jun 2000;35(6):820-2. [Medline].
Lemberg DA, Clarkson CM, Bohane TD, Day AS. Role of esophagogastroduodenoscopy in the initial assessment of children with inflammatory bowel disease. J Gastroenterol Hepatol. Nov 2005;20(11):1696-700. [Medline].
Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn''s disease: effect on localisation and clinical course. Gut. Jun 1992;33(6):779-82. [Medline].
Liu CD, Rolandelli R, Ashley SW, et al. Laparoscopic surgery for inflammatory bowel disease. Am Surg. Dec 1995;61(12):1054-6. [Medline].
Lowney JK, Dietz DW, Birnbaum EH, et al. Is there any difference in recurrence rates in laparoscopic ileocolic resection for Crohn's disease compared with conventional surgery? A long-term, follow-up study. Dis Colon Rectum. Jan 2006;49(1):58-63. [Medline].
Markowitz J, Markowitz JE, Bousvaros A, et al. Workshop report: prevention of postoperative recurrence in Crohn's disease. J Pediatr Gastroenterol Nutr. Aug 2005;41(2):145-51. [Medline].
McClane SJ, Rombeau JL. Anorectal Crohn''s disease. Surg Clin North Am. Feb 2001;81(1):169-83, ix. [Medline].
Paerregaard A, Uldall Urne F. Anthropometry at the time of diagnosis in Danish children with inflammatory bowel disease. Acta Paediatr. Nov 2005;94(11):1682-3. [Medline].
Pilleul F, Godefroy C, Yzebe-Beziat D, et al. Magnetic resonance imaging in Crohn's disease. Gastroenterol Clin Biol. Aug-Sep 2005;29(8-9):803-8. [Medline].
Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn''s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. May 1 1980;302(18):981-7. [Medline].
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn''s disease. N Engl J Med. May 6 1999;340(18):1398-405. [Medline].
Reif S, Lavy A, Keter D, et al. Appendectomy is more frequent but not a risk factor in Crohn''s disease while being protective in ulcerative colitis: a comparison of surgical procedures in inflammatory bowel disease. Am J Gastroenterol. Mar 2001;96(3):829-32. [Medline].
Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn''s recurrence after ileal resection. Gastroenterology. Jun 1995;108(6):1617-21. [Medline].
Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330-1338. [Medline].
Sardinha TC, Wexner SD. Laparoscopy for inflammatory bowel disease: pros and cons. World J Surg. 1998;22:370-374. [Medline].
Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. Aug 2005;11(8):707-12. [Medline].
Song HK, Buzby GP. Nutritional support for Crohn's disease. Surg Clin North Am. 2001;81:103-115. [Medline].
Stronkhorst A, Radema S, Yong SL, et al. CD4 antibody treatment in patients with active Crohn''s disease: a phase 1 dose finding study. Gut. Mar 1997;40(3):320-7. [Medline].
Tromm A, May D, Almus E, et al. Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol. Feb 2001;39(2):137-44. [Medline].
Van Heel DA, McGovern DP, Jewell DP. Crohn''s disease: genetic susceptibility, bacteria, and innate immunity. Lancet. Jun 16 2001;357(9272):1902-4. [Medline].
Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn''s disease. Gastroenterology. Dec 1999;117(6):1278-87. [Medline].
Further Reading
Keywords
Crohn disease, Crohn's disease, regional ileitis, inflammatory bowel disease, IBD, Crohn's inflammation, Crohn inflammation, Crohn colitis, Crohn's colitis, toxic megacolon
